|
Other anticoagulants
Citations 21-30 of 93 total displayed.
|
Past content
(since Jan 2001):
|
- Articles
Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease
- Mark Y. Chan, Mauricio G. Cohen, Christopher K. Dyke, Shelley K. Myles, Laura G. Aberle, Min Lin, James Walder, Steven R. Steinhubl, Ian C. Gilchrist, Neal S. Kleiman, David A. Vorchheimer, Nicholas Chronos, Chiara Melloni, John H. Alexander, Robert A. Harrington, Ross M. Tonkens, Richard C. Becker, and Christopher P. Rusconi
Circulation published May 27, 2008, doi:10.1161/CIRCULATIONAHA.107.745687
[Abstract]
- Correspondence
Response to Letter Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women’s Health Study"
- Robert J. Glynn, Paul M Ridker, Robert Y.L. Zee, Julie E. Buring, and Samuel Z. Goldhaber
Circulation 2008;117:e313, doi:10.1161/CIRCULATIONAHA.107.756437
[Full text]
- Contemporary Reviews in Cardiovascular Medicine
Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
- Jack Hirsh, Martin O’Donnell, and John W. Eikelboom
Circulation 2007;116:552-560, doi:10.1161/CIRCULATIONAHA.106.685974
[Full text]
- Editorials
A Replacement for Warfarin: The Search Continues
- John W. Eikelboom and Jeffrey I. Weitz
Circulation 2007;116:131-133; published online before print as doi:10.1161/CIRCULATIONAHA.107.712349
[Full text]
- Vascular Medicine
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study
- Giancarlo Agnelli, Alexander Gallus, Samuel Z. Goldhaber, Sylvia Haas, Menno V. Huisman, Russel D. Hull, Ajay K. Kakkar, Frank Misselwitz, Sebastian Schellong for the ODIXa-DVT Study Investigators
Circulation 2007;116:180-187; published online before print as doi:10.1161/CIRCULATIONAHA.106.668020
[Abstract]
[Full text]
- Articles
A Replacement for Warfarin. The Search Continues
- John W. Eikelboom and Jeffrey I. Weitz
Circulation published June 18, 2007, doi:10.1161/CIRCULATIONAHA.107.712349
[Abstract]
- Articles
Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939). The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study
- Giancarlo Agnelli, Alexander Gallus, Samuel Z. Goldhaber, Sylvia Haas, Menno V. Huisman, Russel D. Hull, Ajay K. Kakkar, Frank Misselwitz, Sebastian Schellong for the ODIXa-DVT Study Investigators
Circulation published June 18, 2007, doi:10.1161/CIRCULATIONAHA.106.668020
[Abstract]
- Coronary Heart Disease
Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction
- Jessica L. Mega, David A. Morrow, Erika Östör, Maria Dorobantu, Jie Qin, Elliott M. Antman, and Eugene Braunwald
Circulation 2007;115:2822-2828; published online before print as doi:10.1161/CIRCULATIONAHA.106.679548
[Abstract]
[Full text]
- Interventional Cardiology
Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial
- Marc Cohen, Deepak L. Bhatt, John H. Alexander, Gilles Montalescot, Christoph Bode, Timothy Henry, Jean-Francois Tamby, Jan Saaiman, Stanislas Simek, Johannes De Swart on behalf of the SEPIA-PCI Trial Investigators
Circulation 2007;115:2642-2651; published online before print as doi:10.1161/CIRCULATIONAHA.106.653428
[Abstract]
[Full text]
- Articles
Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction
- Jessica L. Mega, David A. Morrow, Erika Östör, Maria Dorobantu, Jie Qin, Elliott M. Antman, and Eugene Braunwald
Circulation published May 21, 2007, doi:10.1161/CIRCULATIONAHA.106.679548
[Abstract]
|
|
